What does clinical leadership look like when you cannot afford a full-time CMO?
We have arrived at the final pillar of the Clinical Governance in FemTech series.
Over the past several weeks, we have worked through six pillars of Clinical Governance in FemTech, and each one has asked a version of the same question: Is your FemTech product built to actually serve the women using it, or just to look like it does?
This final pillar brings it back to the foundation, because none of the other pillars hold up without some form of clinical leadership guiding the organization. And yet for many early-stage FemTech founders, the honest reality is that a full-time Chief Medical Officer is not financially within reach.
So what do you do?
The Waiting Trap
A common mistake early-stage founders make around clinical leadership is treating it as a binary decision. Either we can afford a proper clinical lead or we cannot, so we will wait.
This is the wrong choice, and waiting is expensive in ways that are not immediately obvious.
A product built without clinical leadership embedded in its development accumulates decisions that will need to be revisited later. The cost of correcting those decisions at scale is almost always higher than the cost of getting clinical input earlier, even in a limited form.
The question you need to answer is what clinical leadership looks like at your current stage and budget, not just whether you can afford clinical leadership.
The Minimum Viable Clinical Governance Structure
For a pre-revenue or early-revenue FemTech company, meaningful clinical leadership does not require a full-time hire. It requires a deliberate structure, one that ensures clinical thinking is embedded in how the product is built, even if the person providing that thinking is not in the building every day.
Here’s how this can be applied:
A part-time clinical advisor with defined scope. This is different from a name on a pitch deck. A part-time clinical advisor in a governance role has a specific remit: reviewing product features before they ship, approving clinical claims before they go public, and attending a regular product review meeting where clinical concerns can be raised and addressed. The engagement is structured, documented, and tied to specific deliverables.
The key is defining what the advisor is actually responsible for. It’s not “advising generally” but reviewing the symptom categorization logic before the next sprint, approving the language in the next email campaign, and signing off on the clinical rationale for the new feature before it launches.
A clinical review rhythm. Even without a full-time clinical lead, you can build clinical review into your operating rhythm. A monthly or biweekly session where a clinician reviews recent product decisions, flags concerns, and provides input on what is coming next costs relatively little and prevents the kind of clinical drift that builds up quietly without being noticed.
An Intended Use Statement as the anchor. For a resource-constrained company, the Intended Use Statement does a significant amount of the governance work that a full-time clinical lead would otherwise do. It defines what the product is, what it does, who it is for, and what it must never claim to do. When that document is clear, well-communicated, and genuinely referenced in product and content decisions, it reduces the volume of clinical review required at every stage, because the boundaries are already defined. Read more about the Intended Use Statement here, and reach out if you need help writing one.
Selective clinical depth. Not every part of your product carries the same clinical risk. A resource-constrained company should identify the highest-risk features, the ones where clinical error has the most significant consequences for users, and concentrate clinical oversight there. Not everything needs the same level of scrutiny, but the things that do need it must get it.
Where to Start
It is worth being clear about what a minimum viable clinical governance structure is not.
It is not a clinician who agreed to have their name on your website, a one-time product review that has not been repeated since, or a medical disclaimer that transfers liability to the user. In the earliest days, these may get you through a critical stage. But they are a starting point, not a destination, and as your product grows and regulatory exposure increases, they will not hold up.
If you are an early-stage FemTech founder without structured clinical leadership in place, here’s what you can do.
- Identify one clinician whose expertise is relevant to your product.
- Define a specific, limited scope for their involvement.
- Build a review rhythm around that scope.
- Document what they review and what they approve.
That is clinical leadership, and it does not require a CMO title or a full-time salary but intention, structure, and consistency.
Start where you are, and build clinical oversight that is real, not just implied.
Closing the Series
This is the final article in the series. You can read the articles on all previous pillars here.
I would love to hear your feedback on the series and topics you would like covered in future issues of the Better Woman Health newsletter. Reply to this email or reach out directly. Your input genuinely shapes what comes next.
Better Woman Health is published weekly.
Subscribe at betterwomanhealth.com to get it directly in your inbox.
Clinical Credibility Toolkit
The Clinical Credibility Toolkit is a free resource designed for FemTech founders building digital tools for women’s health.
It includes the Clinical Credibility Scorecard, a 28-question assessment that helps you identify gaps in your clinical foundation, evidence strategy, safety architecture, and investor readiness, and the Red Flag Detection Checklist, a 25-question assessment that tells you whether your symptom-tracking app can actually detect and act on medical red flags, not just log them.
If you are preparing to pitch, pursuing healthcare partnerships, or simply want to know where your product stands clinically, start here.
Access the toolkit → app.ayomide.me
Thanks for reading. See you soon!
Dr. Ayomide O.
FemTech Credibility Advisor
Find me on LinkedIn or Book a 1:1 Call
